Additionally, this triple therapy increased the frequency of T-bet + CD8 + tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME), enhanced the frequency of CD4+ ICOS+ T cells, promoted granzyme B production, and reduced PD-1 expression. This evidence concerns the gene CD8A and neoplasm.